Fierce Pharma

FEBRUARY 6, 2024

In a midstage trial, Eli Lilly’s star diabetes and weight-loss drug tirzepatide showed promise in fatty liver disease, a difficult-to-treat condition that doesn’t yet have an FDA-approved therapy.< | Eli Lilly's star diabetes and weight loss drug tirzepatide showed promise in fatty liver disease with a massive anti-MASH benefit accompanied by a "clinically meaningful" anti-fibrosis effect.

FDA 290

FDA 290

MedCity News

FEBRUARY 6, 2024

The preliminary results from three clinical trials administering gene therapy to address deafness from otoferlin mutations mark inspiring and incredible progress in hearing healthcare.

Healthcare 138

Healthcare Healthcare Biopharma 138

Fierce Pharma

FEBRUARY 6, 2024

Following a slew of cell therapy biotech team-ups, AstraZeneca is taking manufacturing into its own hands. | AstraZeneca is plugging $300 million into a new facility in Rockville, Maryland, to launch its cell therapy platforms in the United States for cancer trials and future commercial supply. In turn, AZ will create more than 150 new jobs.

Manufacturing 287

Manufacturing 287

Pharmaceutical Technology

FEBRUARY 6, 2024

The potentially disastrous consequences of antimicrobial resistance (AMR) were highlighted at the recent World Economic Forum Meeting 2024.

135

135

Advertisement

Distribution

Fierce Pharma

FEBRUARY 6, 2024

Locked in a heated battled with Novo Nordisk’s semaglutide franchise, Eli Lilly’s tirzepatide is beginning to come into its own—both with regards to sales and amid attempts to show the dual GIP/GLP | Locked in a heated battled with Novo Nordisk’s semaglutide franchise, Eli Lilly’s tirzepatide is beginning to come into its own—both with regards to sales and amid attempts to show the dual GIP/GLP-1 agonist can strike out beyond diabetes and obesity.

Sales 260

Sales 260

MedCity News

FEBRUARY 6, 2024

Novartis’s €2.7B acquisition of MorphoSys brings two cancer drug candidates, one of which would give the pharmaceutical giant a way to stand apart from other myelofibrosis treatments. In a separate deal, MorphoSys sold to Incyte its rights to a partnered blood cancer drug.

Pharmaceutical 113

Pharmaceutical FDA Biopharma Pharma 113

MedCity News

FEBRUARY 6, 2024

Primary care is essential to living healthier lives, and we need all forms of it, from small local practices to big health systems and retail chains. Ultimately, it’s going to be all primary care hands on deck, working together to make a lasting change for the health of Americans.

Retail 110

Retail Physicians 110

Fierce Pharma

FEBRUARY 6, 2024

As the U.S. | The U.S. Federal Trade Commission supports a draft guidance that would allow drug pricing be factored into consideration of the government's march-in rights. And the antitrust watchdog is advocating for further scrutiny around "patent thickets" to complement the march-in provision.

Government 226

Government 226

MedCity News

FEBRUARY 6, 2024

Blue Cross Blue Shield of Massachusetts has launched a new reproductive health care team and has partnered with Maven Clinic for 24/7 reproductive health support.

115

115

Fierce Pharma

FEBRUARY 6, 2024

On a day when Vertex revealed trial data that indicate | On a day when Vertex revealed trial data that indicate its next-generation cystic fibrosis (CF) treatment will soon be ready to grab the baton, the Boston company also presented figures that show Trikafta remains formidable. In the fourth quarter, Trikafta raked in $2.33 billion in sales, bringing its 2023 haul to $8.9 billion, a 16% increase from 2022.

Sales 198

Sales 198

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

Pharmaceutical Commerce

FEBRUARY 6, 2024

A cohort study investigates the impact of Senate Bill 2994A and answers the question: does the repeal of school-entry nonmedical vaccination exemptions result in a rise in school vaccinations?

110

110

Fierce Pharma

FEBRUARY 6, 2024

Shortly before Novartis revealed a $2.9 billion buyout of cancer drugmaker MorphoSys, Incyte secured its own piece of the pie. | While Incyte gained more rights to lymphoma med Monjuvi, Novartis claimed the rest of MorphoSys for €2.7B on Monday. Incyte previously bought into a Monjuvi collaboration for $750 million ahead of the drug's 2020 approval.

182

182

MedCity News

FEBRUARY 6, 2024

SaaS startup Ambience Healthcare raised $70 million from investors including OpenAI, Andreessen Horowitz, Optum Ventures and Kleiner Perkins. The San Francisco-based company offers tools to alleviate clinicians’ burnout by helping them with documentation, coding, referrals and after-visit summaries.

Healthcare 105

Healthcare Healthcare 105

pharmaphorum

FEBRUARY 6, 2024

Right after the official launch of the new Apple Vision Pro mixed reality headset, Cedars-Sinai has launched a generative artificial intelligence (genAI) app that will use the technology to provide mental health support for patients.

Patients 90

Patients 90

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Distribution

MedCity News

FEBRUARY 6, 2024

In clinical trials, pharmaceutical companies are seeking to optimize operations and improve efficiency by automating and enhancing processes through Artificial Intelligence (AI) and Machine Learning (ML). One area where this can reap tangible benefits across clinical trials is in data processing. A typical clinical trial generates over 13,000 documents in various formats (text, voice, video, apps, and web entries), making data gathering, organization and analysis challenging.

Safety 103

Safety Electronics Training Pharmaceutical 103

Pharmaceutical Technology

FEBRUARY 6, 2024

Health Canada has approved Chiesi Global Rare Diseases’ MYALEPTA as a treatment for individuals with lipodystrophy, an ultra-rare condition.

98

98

MedCity News

FEBRUARY 6, 2024

Eli Lilly reported 74% of patients treated with tirzepatide achieved resolution of metabolic dysfunction-associated steatohepatitis, or MASH. However, the Phase 2 results showed only “clinically meaningful” improvement in resolving liver fibrosis, a key measure of the drug’s potential competitiveness in a crowded field of contenders.

Competition 100

Competition Patients Biopharma Pharma 100

European Pharmaceutical Review

FEBRUARY 6, 2024

Suanfarma has announced a strategic rebranding initiative to reinforce Suanfarma’s position as a global player in the healthcare sector, both as a distributor of active pharmaceutical ingredients (APIs) and as a contract development and manufacturing organisation (CDMO) in the production of APIs. In this manner, Suanfarma´s sites, Cipan and Rovereto, are now acknowledged as part of a global and unified brand.

Manufacturing 80

Manufacturing Distribution Pharmaceutical Competition 80

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Safety

MedCity News

FEBRUARY 6, 2024

The webinar, scheduled for March 6 at 2pm ET and sponsored by Build My Health, will discuss several topics related to weight management including: an overview of GLP-1 weight loss medication, automation in a subscription-based weight management program, and the rise of provider-to-consumer (PTC) models.

Management 86

Management Physicians Medical 86

Pharmaceutical Commerce

FEBRUARY 6, 2024

Pharma Commerce's new style is built off of the back of our new and improved editorial calendar.

Pharma 105

Pharma 105

pharmaphorum

FEBRUARY 6, 2024

Vertex will use a priority review voucher to speed up FDA review of its new triple therapy for cystic fibrosis, which has just cleared a phase 3 programme

FDA 80

FDA 80

PharmaTimes

FEBRUARY 6, 2024

Hypoxic-ischaemic encephalopathy affects around three million babies worldwide every year

106

106

Advertisement

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

Specialization

pharmaphorum

FEBRUARY 6, 2024

Gene-editing startup Metagenomi and cancer specialist NeOnc Technologies have announced the terms of their initial public offerings

82

82

PharmaVoice

FEBRUARY 6, 2024

With a focus on her “three pillars” of being a CEO, Caroline Loew explains how she’s building a new company culture at an Alkermes spinoff — and a pipeline that offers a next-gen approach to oncology.

69

69

pharmaphorum

FEBRUARY 6, 2024

Novartis has agreed to buy Germany's MorphoSys in a transaction that values the cancer-focused biotech at $2.

Pharma 88

Pharma 88

PharmaVoice

FEBRUARY 6, 2024

The "small molecule penalty" becomes even riskier for investors as the IRA negotiates prices, and VCs and lawmakers are looking to get a jump on those headwinds.

69

69

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Leads

pharmaphorum

FEBRUARY 6, 2024

A $15m initiative between Pfizer and the American Cancer Society aims to tackle unequal access to care in the US.

84

84

Evolve Your Success

FEBRUARY 6, 2024

Mark Copeland joins Samuel Adeyinka to share his medical sales experience in sterile processing and infection prevention. He explains how selling a suite of products in this space allows operating rooms to solve problems efficiently, make their work easier, and even uncover issues they do not know they already have. Mark discusses the role of value analysis in improving their products and services, allowing them to properly address the ever-changing and specific needs of patients.

Medical sales 59

Medical sales Medical Sales Doctors 59

Pharmaceutical Commerce

FEBRUARY 6, 2024

The February issue is centered around third-party logistics providers, including new dynamics and future trends that affect this key supply chain link.

59

59

Clarify Health

FEBRUARY 6, 2024

Medicare Advantage enrollment continues to grow. More than half of all eligible people with Medicare are in a Medicare Advantage plan. But that doesn’t mean it’s been smooth sailing for Medicare Advantage leaders. CMS continues to issue updated policies and brand-new regulations for MA plans to follow, with the overarching goal of improving transparency, easing access to care, and empowering consumer choice.

Networking 52

Networking Insurance Government Management 52

Advertisement

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.

Management